/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
  2. 287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1
287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders · Sep 15, 2026

Manufacturability isn't a late-stage problem. Your initial cell line choice is the most critical CMC decision you don't get to undo.

Investor Pressure for Clinical Data Pushes Companies to Neglect Early Manufacturability

The intense need to show positive clinical data to secure the next funding round forces biotech startups to prioritize speed over everything. Consequently, crucial but time-consuming manufacturability assessments are often postponed, viewed as an 'extra cost' that can be handled later, creating significant downstream technical debt.

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1 thumbnail

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·2 months ago

Your Cell Line is the One CMC Decision You Cannot Undo Later

Downstream purification processes can be modified and optimized throughout a product's lifecycle. However, the cell line selection is effectively permanent once the master cell bank is created. Choosing a non-robust cell line, such as one highly sensitive to minor pH shifts, will create persistent manufacturing challenges for the lifetime of the product.

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1 thumbnail

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·2 months ago

Changing Media After Master Cell Banking Introduces Uncontrolled Process Variability

Altering the cell culture media after a master cell bank (MCB) has been created is a high-risk decision. It forces cells to adapt during the seed train of every GMP run, introducing unpredictable, stochastic scenarios where cell behavior can vary from batch to batch, compromising process robustness and consistency.

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1 thumbnail

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·2 months ago

Assess Drug Manufacturability at Candidate Selection, Not Just PK/PD Data

Companies often prioritize small gains in a drug's activity (PK/PD data) during candidate selection, while ignoring manufacturability. This can lead to selecting a molecule that is extremely difficult or costly to produce, a problem that a slightly less active but more manufacturable alternative would have avoided.

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1 thumbnail

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·2 months ago

Scale-Up to CHO Cells Can Unmask Impurities Hidden in R&D Systems

Low-productivity R&D systems, like HEK cells, can hide product-related impurities such as truncated forms. These impurities are often at levels too low to detect. When the process is scaled up using high-productivity CHO cells, these once-invisible impurities can become a major issue, impacting yield and product quality.

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1 thumbnail

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·2 months ago